News

23 May 2017

Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference

LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signi…

Read more

23 May 2017

Holding(s) in Company

Read more

18 May 2017

Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option

LONDON, May 18, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signif…

Read more

16 May 2017

Partial Exercise of Over-Allotment Option

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Read more

9 May 2017

Holding(s) in Company

 

Read more

8 May 2017

Holding(s) in Company

 

Read more

5 May 2017

Holding(s) in Company



Read more

5 May 2017

Holding(s) in Company

Read more

5 May 2017

Holding(s) in Company

 

Read more

3 May 2017

Holding(s) in Company

 

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us